Mirion Technologies Earnings Call Shows Orders Surging

Mirion Technologies, Inc. ((MIR)) has held its Q1 earnings call. Read on for the main highlights of the call.

Mirion Technologies’ latest earnings call struck a confident tone, with management emphasizing strong order momentum, a sharply higher backlog, and growing contributions from recent acquisitions. Executives acknowledged short‑term pressures on margins and cash flow, but repeatedly framed these as manageable timing and mix issues, outweighed by healthy demand in nuclear power, SMRs, and medical markets.

Order Book Surges on Large Deals and SMR Wins

Mirion reported total orders up 42% year over year to $288 million, including Paragon and CertRec, while orders excluding M&A rose 19% to $241 million. The company secured about $50 million of large opportunity orders in Q1 and followed that with a $35 million SMR‑related award in April, underscoring momentum in high‑value projects.

Backlog Hits $1.1 Billion, Securing Multi‑Quarter Visibility

The backlog swelled to $1.1 billion, up 38% including M&A and 19% on an organic basis, marking a step change after two strong ordering quarters. Management highlighted that this enlarged backlog enhances revenue visibility over multiple quarters and supports confidence in delivering on medium‑term growth targets.

Revenue Jumps 28% with Modest but Steady Organic Growth

Consolidated Q1 revenue reached $258 million, a 28% increase versus last year, reflecting both acquisitions and underlying demand. Organic revenue growth came in at 3%, matching guidance and reinforcing management’s message of steady core expansion despite some regional and mix headwinds.

Adjusted EBITDA and EPS Climb Despite Margin Pressure

Adjusted EBITDA rose 16% to $54 million, with adjusted EPS at $0.10 for the quarter, which management noted would have been $0.08 under the prior methodology. While margins compressed, the team argued that earnings growth and expanding scale position the company for future margin recovery as integration efforts take hold.

Paragon and CertRec Deals Fuel Growth and Cross‑Selling

Paragon delivered strong first‑quarter revenue growth of roughly 45% and contributed meaningfully to both orders and sales, with M&A adding about $43 million from Paragon and $47 million combined with CertRec. Early commercial synergies are already evident, as Mirion cited incremental order wins and cross‑sell opportunities emerging from the expanded portfolio.

Nuclear and SMR Businesses Gain Strategic Traction

Nuclear & Safety revenue climbed 39% to $186 million, with nuclear power orders excluding M&A up 15% and revenue up 4% despite difficult comparisons. SMR orders totaled about $15 million in Q1 plus the $35 million April award, and SMR revenue now near 2% of total is expected to exceed 3% by year‑end, signaling a growing niche.

Medical Segment Rebounds with RTQA Strength and Key Wins

Medical revenue increased 5% to $72 million, with organic growth of about 4% as the segment continued to recover. RTQA delivered double‑digit organic growth driven by software demand and a major radiation‑tolerant camera order linked to the Varian partnership, while nuclear medicine remains on track for double‑digit organic growth in 2026.

Capital Returns and Seasonally Light Cash Generation

Mirion deployed roughly $16 million under its $100 million share repurchase program in Q1, buying about 700,000 shares as part of its capital return strategy. Adjusted free cash flow was $11 million, which management labeled seasonally light, and they reiterated expectations for stronger cash generation in later quarters.

Guidance and Near‑Term Outlook Remain Firm

Management reaffirmed its 2026 outlook, adjusting EPS slightly for a one‑time CEO retention grant, and pointed to solid Q1 metrics as validation. For Q2 they anticipate orders rising 15%–20% sequentially, low single‑digit organic revenue growth, roughly flat adjusted EBITDA margins versus last year, and continued progress toward Paragon’s low‑20s margins and the longer‑term 30% EBITDA goal by 2028.

Margins Compress on M&A and Mix, but Seen as Transitory

Adjusted EBITDA margins contracted in Q1 even as absolute EBITDA increased, which management attributed mainly to the lower initial margins of acquired businesses. They also cited one‑time items in the prior‑year quarter and an unfavorable mix shift in sensing and North American volumes, noting that about half of the pressure came from M&A effects.

Working Capital and Cash Timing Weigh on Free Cash Flow

The modest $11 million of adjusted free cash flow was tied largely to weaker project inflows versus last year and timing in receivables and inventory. Management stressed that project cash flows are inherently lumpy but emphasized that accounts receivable, inventory, and project cash management remain key focus areas for further improvement.

Regional New‑Build Slowdown and Dosimetry Comps Create Noise

Lower new‑build activity in Asia, especially China and Korea, dampened nuclear power revenue growth and created tougher near‑term comparisons after strong prior shipments. Additionally, the dosimetry services business showed a slight organic decline due to a large hardware order last year, masking what management said would have been low single‑digit growth in the core.

Paragon’s Near‑Term Dilution Offsets by Long‑Term Margin Ambitions

While Paragon is currently dilutive to Mirion’s consolidated adjusted EBITDA margin, leadership insisted it remains a key value driver over time. They reiterated targets for Paragon to reach low‑20s EBITDA margins and confirmed a broader company‑wide ambition of exceeding 30% adjusted EBITDA by 2028 as integration and scale benefits accrue.

Mirion’s call painted a picture of a company trading near‑term margin and cash volatility for stronger long‑term positioning in nuclear and medical markets. With accelerating orders, a record backlog, and acquisition‑driven scale, management argued that operational execution and integration will be the main levers to translate today’s commercial momentum into durable earnings growth for shareholders.